Sexual effects
1Spontaneous erections were observed in the pilot; this is not an approved treatment indication.
What does it do?
Unapproved melanocortin agonist used in community tanning/sexual-function practices. Nasal and topical products lack established human efficacy or dosing equivalence.
Approved & studied uses
Community uses Reported, unvalidated
Pigmentation
15Tanning and localized/vitiligo claims; not proven UV protection.
Sexual response
15Libido/arousal/erection effects, with priapism risk.
Appetite/metabolism
15Appetite, fat/glucose claims require stronger clinical evidence.
Reasons people report using it; these do not establish benefit.15
Evidence limits
View research →Long-term risk, reliable product quality, and benefit-risk balance for tanning.1
5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Nausea and fatigue
The pilot reported nausea at most dose levels; fatigue or sleepiness occurred at higher doses.1
No FDA-approved Melanotan II product. Afamelanotide/Scenesse approval does not apply to Melanotan II.
Molecular information
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Residue count only · sequence not verified4
An exact sequence has not been verified for this formulation.
Length7 amino acids
Molecular weight · Da1024.2 Da
Formula, sequence notation & identity
Molecular formulaC50H69N15O94
Melanotan II, a cyclic, acetylated melanocortin analog with an amidated terminus.
Parent-peptide identity; a salt or formulated product can have a different total mass.
Pharmacokinetics
How long does it stay in the body?
Class inferenceNot independently confirmed
Reference half-life1 hour14
Route / formulationSource page: Injectable. Exact PK route not verified.
The source identifies this as a class-level inference, not a measured half-life for this compound. Pep-Pedia identifies this as a class inference from human melanotan-I data. It is not a measured melanotan-II half-life.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Dorr et al. 1996 J Natl Cancer Inst 88(17):1196-1201 (MT-I human subQ PK; class inference applied to MT-II)
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Very small pigmentation signal
Two of three volunteers had increased pigmentation one week after the pilot course. The sample cannot establish a reliable expected response.1
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 38 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 23 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 7 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1596 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous injection | 0.01 mg/kg — initial exposure | Initial active dose | Assess tanning and acute tolerabilityHuman study | 2 weeks | 1 |
Population Three healthy male volunteers Context Small dose-escalation experiment; not a home-use regimen. Source dose wording 0.01 mg/kg initially; increased in 0.005 mg/kg steps to 0.025 or 0.03 mg/kg | |||||
| SubQSubcutaneous injection | 0.025 mg/kg — escalation endpoint | After 0.005 mg/kg escalation steps | Assess tanning and acute tolerabilityHuman study | 2 weeks | 1 |
Population Three healthy male volunteers Context Small dose-escalation experiment; not a home-use regimen. Source dose wording 0.01 mg/kg initially; increased in 0.005 mg/kg steps to 0.025 or 0.03 mg/kg | |||||
| SubQSubcutaneous injection | 0.03 mg/kg — escalation endpoint | After 0.005 mg/kg escalation steps | Assess tanning and acute tolerabilityHuman study | 2 weeks | 1 |
Population Three healthy male volunteers Context Small dose-escalation experiment; not a home-use regimen. Source dose wording 0.01 mg/kg initially; increased in 0.005 mg/kg steps to 0.025 or 0.03 mg/kg | |||||
| SubQ | 0.25 mg | Daily | Initial LoadingReference report | 4-8 weeks on, 4 weeks off | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Injectable | |||||
| SubQ | 0.5-1 mg | 2-3x weekly | Tanning MaintenanceReference report | 4-8 weeks on, 4 weeks off | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Injectable | |||||
| SubQ | 0.5-1 mg | As needed | Sexual EnhancementReference report | 4-8 weeks on, 4 weeks off | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Injectable | |||||
| SubQ | 0.1-0.25 mg | Every other day | Minimal Side EffectsReference report | 4-8 weeks on, 4 weeks off | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Injectable | |||||
| SubQ | 0.5 mg | 2x weekly | PhotoprotectionReference report | 4-8 weeks on, 4 weeks off | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Injectable | |||||
| TopicalTopical cream | 0.5-1 mg/ml | Once daily | Facial TanningReference report | 6-12 weeks continuous use | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Topical | |||||
| TopicalTopical solution | 1-2 mg/ml | Twice daily | Body ApplicationReference report | 6-12 weeks continuous use | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Topical | |||||
| TopicalTopical + UV | 2 mg/ml | Twice daily | Vitiligo PatchesReference report | 6-12 weeks continuous use | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Topical | |||||
| IntranasalNasal spray | 0.5 mg | Once daily | Initial ToleranceReference report | 4-6 weeks | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Nasal | |||||
| IntranasalNasal spray | 1 mg | Daily or as needed | Standard ProtocolReference report | 4-6 weeks | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Nasal | |||||
| IntranasalNasal spray | 1-2 mg | 2-3x weekly | MaintenanceReference report | 4-6 weeks | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-8 weeks on, 4 weeks off
- Break
- 4 weeks minimum to assess melanin fading
Reported timing
Morning for tanning effects, evening for sexual effects (or 2-4 hours before)
Topical
- Use period
- 6-12 weeks continuous use
- Break
- 4-6 weeks to assess results
Reported timing
Apply to clean skin, allow to absorb before sun exposure
Nasal
- Use period
- 4-6 weeks
- Break
- 4 weeks between cycles
Reported timing
Morning for tanning, 1-2 hours before for sexual effects
Side effects & safety
Nausea and fatigue
The pilot reported nausea at most dose levels; fatigue or sleepiness occurred at higher doses.
1Prolonged erections
The pilot observed intermittent erections over 1–5 hours after dosing; FDA also cites published priapism reports.
12Serious case reports
FDA lists reports including melanoma, neurologic illness and sympathomimetic toxicity. Reports do not establish incidence or prove causation.
2Product uncertainty
FDA flags immune-reaction risks associated with peptide aggregation and impurities in compounded products.
2Oral pigmentation
A case report found persistent gum discoloration after discontinuation; this was pigmentation, not a diagnosis of melanoma.
5Systemic effects
Nausea, flushing, fatigue, headache and blood-pressure changes; changing moles require assessment.
Urgent symptoms
Painful prolonged erection, chest pain, severe headache/vision change, persistent vomiting or allergy.
Local routes
Skin irritation/patchy pigment; nasal bleeding, infection, smell loss or congestion.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
PT-141
Caution reportedOverlapping receptor/BP effects.15
Reference report · Pep-Pedia label: Use CautionAlpha-MSH
Avoidance reportedOverlapping receptor stimulation.15
Reference report · Pep-Pedia label: Avoid CombinationCialis/Viagra
Caution reportedPriapism/cardiovascular concern.15
Reference report · Pep-Pedia label: Monitor CombinationBlood-pressure medicines
Caution reportedUnpredictable pressure effects.15
Reference report · Evidence context: Monitor combinationAppetite suppressants
Caution reportedExcess intake reduction.15
Reference report · Pep-Pedia label: Monitor CombinationBPC-157
Unverified pairingSafety unestablished.15
Reference report · Pep-Pedia label: CompatibleGrowth-hormone peptides
Unverified pairingSafety unestablished.15
Reference report · Pep-Pedia label: CompatibleThyroid medicines
Unverified pairingNo direct evidence cited.15
Reference report · Evidence context: UnknownOther melanocortin peptides, including PT-141
Not establishedCombination safety was not established in the cited single-compound pilot. Similar reported effects do not validate stacking.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
No formulation-specific human reconstitution instructions were verified for this research powder.1
Diluent and storage
A compatible solvent, concentration, preservative and beyond-use period cannot be inferred from vial mass. The cited source does not validate a universal bacteriostatic-water recipe.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 30 days. · The source specifies protection from light.
The source describes gentle mixing and avoiding vigorous shaking.
Topical
The topical steps describe a propylene-glycol vehicle and penetration-enhancing cream base.
- Solvents mentioned
- Propylene glycol
- Reported parameters
- Reported topical pH: 5.5–6.5. · The source describes an airless container and protection from light.
The generic BAC-water banner is not treated as topical formulation guidance.
Nasal
Pep-Pedia reports a nasal concentration and assumed pump volume.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 10 mg/mL at 0.1 mL per spray gives 1 mg per spray. · The pump volume must be calibrated; 0.1 mL is not universal. · Reported storage: refrigerated and light-protected; the page banner gives 30 days.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite to off-white lyophilized powderReported appearanceClear to pale yellow when reconstitutedReported variationProtect from light exposureReported concernBrown or dark colored powderReported concernCloudy solution after mixingReported appearanceVacuum sealed vial
15Vial sizes
10mg7
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.15
Full storage notes from Pep-Pedia
15Refrigerate reconstituted peptide, protect from light
Refrigerate cream, use within 30 days
Refrigerate spray bottle, keep upright
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Limited human dataSource context
Source compatibility/photoprotection claims do not establish safety; tanning does not remove UV risk.
Compound identity & other names
A melanocortin agonist studied for pigmentation and erectile responses. Early human findings are small and short term, while serious adverse events have been reported; it is not an established tanning medicine.
Other names: Melanotan 2 · MT-2 · MT-II · MT2
No FDA-approved Melanotan II product. Afamelanotide/Scenesse approval does not apply to Melanotan II.
How it may work
MC1 pigmentation and broader melanocortin appetite/arousal signaling; route-specific exposure remains uncertain.15
Pigmentation signal in only three volunteers
A 1996 phase I pilot found increased pigmentation in two of three men. Nausea occurred at most tested doses; the highest dose caused moderate sleepiness and fatigue in one of two recipients.
1Safety uncertainty is substantial
FDA cites reports of melanoma, priapism, and serious neurologic/toxic reactions. Case reports flag possible harm without establishing frequency or proving causation.
2New report of persistent oral pigmentation
A 2026 case describes gum and cheek pigmentation during self-injection. Gum pigmentation was still visible three months after stopping. The report cannot establish how frequently this occurs.
5Research areas and evidence gaps
Sexual effects. Spontaneous erections were observed in the pilot; this is not an approved treatment indication.1
- Long-term risk, reliable product quality, and benefit-risk balance for tanning.
- Whether any skin-color change provides meaningful protection; tanning is not evidence that UV exposure is safe.
Community reports Unvalidated
PepPedia describes tanning, appetite, and libido use; the claimed benefits are broader than the pilot evidence.6
PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations.
Search coverage and review status
Added a 2026 case of persistent oral pigmentation; a case report cannot estimate incidence or causation.
- Checked
- 2026-10-12
- Search
- "melanotan" 2025 2026
- Catalog
- Pep-Pedia ↗ · 6 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Melanotan-II: pilot phase I studyAbstract checked
AI-PREPARED SUMMARY
A three-man pilot observed pigmentation and erectile effects, alongside nausea and dose-limiting fatigue; it cannot establish chronic tanning safety.
Pigmentation signal in only three volunteers
A 1996 phase I pilot found increased pigmentation in two of three men. Nausea occurred at most tested doses; the highest dose caused moderate sleepiness and fatigue in one of two recipients.
2FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
Regulatory safety assessment.
Safety uncertainty is substantial
FDA cites reports of melanoma, priapism, and serious neurologic/toxic reactions. Case reports flag possible harm without establishing frequency or proving causation.
3FDA notice concerning unapproved Melanotan IIPrimary source checked
AI-PREPARED SUMMARY
FDA describes Melanotan II as an unapproved new drug.
4PubChem: Melanotan II, CID 92432Primary source checked
AI-PREPARED SUMMARY
Chemical identity record: cyclic seven-residue peptide, C50H69N15O9, average molecular weight 1024.2 g/mol.
5Changes in Oral Mucosa Associated with Melanotan II Injections: A Case ReportAbstract checked
AI-PREPARED SUMMARY
One patient developed gingival and cheek pigmentation after 64 days of self-administered injections. Cheek pigmentation nearly cleared after stopping; gingival discoloration persisted at three months. A case cannot estimate incidence.
New report of persistent oral pigmentation
A 2026 case describes gum and cheek pigmentation during self-injection. Gum pigmentation was still visible three months after stopping. The report cannot establish how frequently this occurs.
Additional research · Checked 2026-10-12
6PepPedia: reported practices (accessed October 12, 2026)Community source checked
AI-PREPARED SUMMARY
Secondary editorial account of discussed practices; not a clinical trial or representative survey.
7Research catalog: labeled quantitiesCatalog checked
AI-PREPARED SUMMARY
Lists a 10 mg lyophilized vial. Quantity examples only; vendor quality and suitability are not endorsed.
8Cardiovascular Effects Assessment (2018)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Transient pulse and blood-pressure increases are claimed in monitored humans, but the card provides no original study link or event rates.
Reported population / model
Human
Reported study details
Various doses · Acute monitoring · Mild BP elevation
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Photoprotection in Fair-Skinned Individuals (2015)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source claims less UV erythema in fair-skinned people; no study link is supplied and tanning does not establish melanoma protection.
Reported population / model
Human (Fitzpatrick Type I-II)
Reported study details
0.1mg/kg · 3 months · Reduced sunburn incidence
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Female Sexual Arousal Disorder Trial (2004)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source attributes a female-arousal trial to Melanotan II; compound attribution needs verification because related melanocortins have separate trials.
Reported population / model
Human (Female)
Reported study details
0.025mg/kg · Single dose · 73% reported arousal
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Appetite and Food Intake Study (2001)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A 15% food-intake reduction and modest weight loss are claimed; the original human trial is not linked.
Reported population / model
Human
Reported study details
1mg daily · 6 weeks · 15% reduction in caloric intake
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Phase II Trial of Melanotan II in Erectile Dysfunction (2000)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports an 80% erectile response in men and onset within one to two hours; study duration and compound attribution need verification.
Reported population / model
Human
Reported study details
0.025mg/kg · 3 months · 80% response rate
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13Melanogenesis and UV Protection Study (1999)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Greater pigmentation and UV-response measures are claimed; the dose/formulation may overlap Melanotan I research and needs confirmation.
Reported population / model
Human
Reported study details
0.16mg/kg daily · 10 days · Increased melanin density
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Pep-Pedia: Melanotan II — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 1 hr and a peak time of 30 min. Stated attribution: Dorr et al. 1996 J Natl Cancer Inst 88(17):1196-1201 (MT-I human subQ PK; class inference applied to MT-II). The source identifies this as a class-level inference, not a measured half-life for this compound. Pep-Pedia identifies this as a class inference from human melanotan-I data. It is not a measured melanotan-II half-life. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
15Pep-Pedia: Melanotan II — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12